Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- PMID: 31875506
- DOI: 10.1056/NEJMc1915739
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Comment in
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply.N Engl J Med. 2020 Jan 2;382(1):93-94. doi: 10.1056/NEJMc1915739. N Engl J Med. 2020. PMID: 31875508 No abstract available.
Comment on
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical